Tatsuhiko Tachibana

List of Publications by Year
in descending order

35 papers	**2,735** citations	430874 **18** h-index	377865 **34** g-index
37 all docs	**37** docs citations	**37** times ranked	**2443** citing authors

#	ARTICLE	IF	CITATIONS
1	Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation. Pharmaceuticals, 2022, 15, 508.	3.8	7
2	Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering. MAbs, 2022, 14, 2068213.	5.2	2
3	Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans. Clinical Pharmacokinetics, 2021, 60, 111-120.	3.5	6
4	Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective *In Vivo* without Systemic Immune Activation. Cancer Discovery, 2021, 11, 158-175.	9.4	57
5	A Novel Total Drug Assay for Quantification of Anti-C5 Therapeutic Monoclonal Antibody in the Presence of Abundant Target. AAPS Journal, 2021, 23, 21.	4.4	2
6	Analysis of Non-linear Pharmacokinetics of P-Glycoprotein Substrates in a Microfluidic Device Using a Mathematical Model that Includes an Unstirred Water Layer (UWL) Compartment. Pharmaceutical Research, 2021, 38, 1031-1039.	3.5	0
7	Estimation of Clearance and Bioavailability of Therapeutic Monoclonal Antibodies from Only Subcutaneous Injection Data in Humans Based on Comprehensive Analysis of Clinical Data. Clinical Pharmacokinetics, 2021, 60, 1325-1334.	3.5	4
8	Quantitative prediction of P‐glycoprotein‐mediated drug–drug interactions and intestinal absorption using humanized mice. British Journal of Pharmacology, 2021, 178, 4335-4351.	5.4	7
9	Antibody-based therapeutics. Drug Metabolism and Pharmacokinetics, 2019, 34, 1-2.	2.2	1
10	Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering. Drug Metabolism and Pharmacokinetics, 2019, 34, 25-41.	2.2	21
11	Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. PLoS ONE, 2018, 13, e0209509.	2.5	38
12	Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey. Xenobiotica, 2017, 47, 194-201.	1.1	5
13	Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human. Drug Metabolism and Pharmacokinetics, 2017, 32, 208-217.	2.2	20
14	Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. MAbs, 2017, 9, 844-853.	5.2	18
15	Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Scientific Reports, 2017, 7, 1080.	3.3	79
16	Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thrombosis and Haemostasis, 2017, 117, 1348-1357.	3.4	141
17	PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody–antigen binding model. Drug Metabolism and Pharmacokinetics, 2016, 31, 123-132.	2.2	9
18	Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering. Journal of Immunology, 2015, 195, 3198-3205.	0.8	28

#	Article	IF	Citations
19	Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica, 2014, 44, 1127-1134.	1.1	22
20	Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo. PLoS ONE, 2013, 8, e63236.	2.5	75
21	Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity. PLoS ONE, 2013, 8, e57479.	2.5	246
22	A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nature Medicine, 2012, 18, 1570-1574.	30.7	407
23	Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from their In Vitro Km Values. Pharmaceutical Research, 2012, 29, 651-668.	3.5	47
24	The importance of characterization of FITC-labeled antibodies used in tissue cross-reactivity studies. Acta Histochemica, 2011, 113, 472-476.	1.8	10
25	Predicting Drug – Drug Interactions Involving the Inhibition of Intestinal CYP3A4 and P-Glycoprotein. Current Drug Metabolism, 2010, 11, 762-777.	1.2	57
26	Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates. Pharmaceutical Research, 2010, 27, 442-446.	3.5	85
27	Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nature Biotechnology, 2010, 28, 1203-1207.	17.5	286
28	Extrapolation of In Vitro Metabolic and P-Glycoprotein-Mediated Transport Data to In Vivo by Modeling and Simulations. , 2010, , 299-315.		2
29	New method for the simultaneous estimation of intrinsic hepatic clearance and protein binding by matrix inhibition. Biopharmaceutics and Drug Disposition, 2008, 29, 7-16.	1.9	10
30	Regulation of CAPRICE Transcription by MYB Proteins for Root Epidermis Differentiation in Arabidopsis. Plant and Cell Physiology, 2005, 46, 817-826.	3.1	109
31	Correction of Permeability with Pore Radius of Tight Junctions in Caco-2 Monolayers Improves the Prediction of the Dose Fraction of Hydrophilic Drugs Absorbed by Humans. Pharmaceutical Research, 2004, 21, 749-755.	3.5	72
32	Evaluation of Methods for Predicting Drug-drug Interactions by Monte Carlo Simulation. Drug Metabolism and Pharmacokinetics, 2003, 18, 121-127.	2.2	22
33	Role of a positive regulator of root hair development,CAPRICE,inArabidopsisroot epidermal cell differentiation. Development (Cambridge), 2002, 129, 5409-5419.	2.5	303
34	Regulatory systems of root patterning. Journal of Plant Research, 1998, 111, 315-321.	2.4	1
35	Epidermal Cell Differentiation inArabidopsisDetermined by aMybHomolog,CPC. Science, 1997, 277, 1113-1116.	12.6	535